

## Fujifilm to invest 10B Yen in Bio CDMO biz

08 January 2019 | News | By Manbeena Chawla

**This new round of investments will include the addition of 2000L single use cell culture manufacturing trains, cell culture purification suites and new microbial recovery suites to its existing facilities in North Carolina.**



FUJIFILM Corporation announced plans to invest approximately JPY 10 billion (approximately \$90 million U.S. dollars) in order to expand its Bio Contract Development and Manufacturing Organization (CDMO) Business. This investment will include the expansion of existing production facilities at its North Carolina location to support the growing needs of its customer portfolio. Further investments are planned at the company's other locations; details shall be announced in first quarter of 2019.

FUJIFILM Diosynth Biotechnologies (FDB), is a leading CDMO with demonstrated leadership in the development and manufacture of recombinant biopharmaceuticals and gene therapies. Fujifilm is investing in FDB's facilities to increase production capacity to meet its growing customer demands.

This new round of investments will include the addition of 2000L single use cell culture manufacturing trains, cell culture purification suites and new microbial recovery suites to its existing facilities in North Carolina. These additions will increase cell culture manufacturing capacity by approximately 25% and microbial capacity by approximately 50% at its North Carolina location. The company expects that the increased production capacity will be ready for cGMP manufacture by early 2020.